Intrexon Corp (XON) 39.30 $XON
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Critical Alerts For Apple, Regulus Therapeutics, Intrexon, Tempur Sealy and SINA Released By InvestorsObserver
PR Newswire - Fri Feb 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, RGLS, XON, TPX and SINA.
SINA: 38.37 (+0.59), TPX: 55.62 (+1.71), XON: 39.30 (+1.05), RGLS: 16.85 (-0.13), AAPL: 127.08 (+0.62)
Intrexon buys Belgian biopharma firm
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:29AM CST
XON: 39.30 (+1.05)
Living Biofactories in Your Prescription Bottle?
PR Newswire Europe - Fri Feb 13, 6:15AM CST
- Belgium's ActoGeniX to Join Intrexon
XON: 39.30 (+1.05)
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Fri Feb 13, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax(TM)) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Wednesday, February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 39.30 (+1.05)
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Wed Feb 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated statistically significant efficacy of SGX943 in a mouse model of acute, lethal pneumonic melioidosis. The data was presented in an oral presentation at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Tuesday, February 10, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 39.30 (+1.05)
Why Intrexon Corp's Shares are Up 14% Today
Maxx Chatsko, The Motley Fool - Motley Fool - Tue Feb 10, 1:05PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of biotech billionaire Randal Kirk's flagship...
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 11:45AM CST
AMKR: 8.90 (-0.02), AXR: 5.06 (+0.09), APDN: 3.45 (+0.05), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), NBG: 1.61 (+0.18), PFNX: 12.45 (+0.29), SSNI: 9.15 (+0.36), ARO: 3.63 (+0.04), COUP: 11.06 (-0.07), ANTH: 3.84 (+0.06), NILE: 29.02 (+0.07), MPO: 1.00 (-0.02), QLYS: 47.95 (+1.46), DF: 16.19 (-0.11), FNJN: 2.77 (-0.36), PGN: 2.88 (-0.07), RCON: 2.11 (+0.15), MERU: 2.74 (-0.01), BDL: 34.03 (-0.42)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Intrexon and Ziopharm set for opening gaps
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:06AM CST
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Synthetic Biologics Announces Positive Topline Results from Phase 1b Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection
PR Newswire - Tue Feb 10, 5:56AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
SYN: 2.13 (+0.18), XON: 39.30 (+1.05)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Thu Feb 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 17th Annual BIO CEO Investor Conference in New York City, on Tuesday, February 10, 2015 at 1:30 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
XON: 39.30 (+1.05)
Why Intrexon And Ziopharm Investors Now Face Increased Risk Both Short And Long-Term
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 5:38PM CST
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Synthetic Biologics to Present at the 2015 BIO CEO & Investor Conference
PR Newswire - Tue Feb 03, 5:56AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 9, 2015, at 1:30 p.m. (ET) at the Waldorf Astoria (Conrad room) in New York.
SYN: 2.13 (+0.18), XON: 39.30 (+1.05)
Histogenics Corporation Announces the Appointment of David Gill to Its Board of Directors and Chairman of Audit Committee
GlobeNewswire - Mon Feb 02, 3:11PM CST
Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the appointment of David Gill to its board of directors and chairman of the audit committee. Mr. Gill is currently the Chief Financial Officer of EndoChoice, Inc., a medical device company which provides devices, diagnostics, infection control and imaging for specialists treating a wide range of gastrointestinal (GI) diseases.
HSGX: 8.61 (-0.07), XON: 39.30 (+1.05)
Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Mon Feb 02, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from two biodefense programs at the upcoming American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting on February 9-11, 2015 to be held at the Washington Marriott Wardman Park, 2660 Woodley Rd. NW.
XON: 39.30 (+1.05)
Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine
PR Newswire - Thu Jan 29, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating enhanced immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). VeloThrax(TM) employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM), has been previously demonstrated to enhance the thermostability of VeloThrax(TM), enabling distribution without cold chain requirements. In this work, the use of two adjuvants, aluminum hydroxide and Glycopyranoside Lipid A (GLA) in conjunction with ThermoVax(TM), was demonstrated to further enhance the immunogenicity and rapid action of the vaccine. The results were published online in the Journal of Pharmaceutical Sciences and are available at the following link: http://onlinelibrary.wiley.com/doi/10.1002/jp...26F.f01t03 .
XON: 39.30 (+1.05)
InsiderInsights.com Daily Round Up 1/27/15: OKSB, OAS, XON, MLNK
InsiderInsights - at Seeking Alpha - Wed Jan 28, 10:20AM CST
MCK: 224.89 (+0.12), SFNC: 39.71 (-0.58), XON: 39.30 (+1.05), WFC: 55.33 (+0.47), MLNK: 3.78 (+0.04), GRH: 0.75 (-0.04), LUV: 43.30 (-0.20), OKSB: 16.51 (+0.09), DFS: 59.89 (+0.46), AGRX: 8.57 (-0.41), IBM: 160.40 (+1.88), CDNA: 6.30 (-0.14), FANG: 73.46 (+0.49), AAPL: 127.08 (+0.62), SNDK: 82.81 (+0.51), OAS: 16.84 (-0.03), URI: 92.98 (+1.41)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Critical Alerts For Apple, Regulus Therapeutics, Intrexon, Tempur Sealy and SINA Released By InvestorsObserver
PR Newswire - Fri Feb 13, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, RGLS, XON, TPX and SINA.
SINA: 38.37 (+0.59), TPX: 55.62 (+1.71), XON: 39.30 (+1.05), RGLS: 16.85 (-0.13), AAPL: 127.08 (+0.62)
Intrexon buys Belgian biopharma firm
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:29AM CST
XON: 39.30 (+1.05)
Living Biofactories in Your Prescription Bottle?
PR Newswire Europe - Fri Feb 13, 6:15AM CST
- Belgium's ActoGeniX to Join Intrexon
XON: 39.30 (+1.05)
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Fri Feb 13, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax(TM)) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Wednesday, February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 39.30 (+1.05)
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Wed Feb 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated statistically significant efficacy of SGX943 in a mouse model of acute, lethal pneumonic melioidosis. The data was presented in an oral presentation at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Tuesday, February 10, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 39.30 (+1.05)
Why Intrexon Corp's Shares are Up 14% Today
Maxx Chatsko, The Motley Fool - Motley Fool - Tue Feb 10, 1:05PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of biotech billionaire Randal Kirk's flagship...
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 11:45AM CST
AMKR: 8.90 (-0.02), AXR: 5.06 (+0.09), APDN: 3.45 (+0.05), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), NBG: 1.61 (+0.18), PFNX: 12.45 (+0.29), SSNI: 9.15 (+0.36), ARO: 3.63 (+0.04), COUP: 11.06 (-0.07), ANTH: 3.84 (+0.06), NILE: 29.02 (+0.07), MPO: 1.00 (-0.02), QLYS: 47.95 (+1.46), DF: 16.19 (-0.11), FNJN: 2.77 (-0.36), PGN: 2.88 (-0.07), RCON: 2.11 (+0.15), MERU: 2.74 (-0.01), BDL: 34.03 (-0.42)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Intrexon and Ziopharm set for opening gaps
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:06AM CST
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Synthetic Biologics Announces Positive Topline Results from Phase 1b Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection
PR Newswire - Tue Feb 10, 5:56AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
SYN: 2.13 (+0.18), XON: 39.30 (+1.05)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Thu Feb 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 17th Annual BIO CEO Investor Conference in New York City, on Tuesday, February 10, 2015 at 1:30 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
XON: 39.30 (+1.05)
Why Intrexon And Ziopharm Investors Now Face Increased Risk Both Short And Long-Term
Investing Healthcare - at Seeking Alpha - Tue Feb 03, 5:38PM CST
ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05)
Synthetic Biologics to Present at the 2015 BIO CEO & Investor Conference
PR Newswire - Tue Feb 03, 5:56AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 9, 2015, at 1:30 p.m. (ET) at the Waldorf Astoria (Conrad room) in New York.
SYN: 2.13 (+0.18), XON: 39.30 (+1.05)
Histogenics Corporation Announces the Appointment of David Gill to Its Board of Directors and Chairman of Audit Committee
GlobeNewswire - Mon Feb 02, 3:11PM CST
Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the appointment of David Gill to its board of directors and chairman of the audit committee. Mr. Gill is currently the Chief Financial Officer of EndoChoice, Inc., a medical device company which provides devices, diagnostics, infection control and imaging for specialists treating a wide range of gastrointestinal (GI) diseases.
HSGX: 8.61 (-0.07), XON: 39.30 (+1.05)
Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Mon Feb 02, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from two biodefense programs at the upcoming American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research Meeting on February 9-11, 2015 to be held at the Washington Marriott Wardman Park, 2660 Woodley Rd. NW.
XON: 39.30 (+1.05)
Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine
PR Newswire - Thu Jan 29, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating enhanced immunogenicity and rapid action of its anthrax vaccine, VeloThrax(TM). VeloThrax(TM) employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM), has been previously demonstrated to enhance the thermostability of VeloThrax(TM), enabling distribution without cold chain requirements. In this work, the use of two adjuvants, aluminum hydroxide and Glycopyranoside Lipid A (GLA) in conjunction with ThermoVax(TM), was demonstrated to further enhance the immunogenicity and rapid action of the vaccine. The results were published online in the Journal of Pharmaceutical Sciences and are available at the following link: http://onlinelibrary.wiley.com/doi/10.1002/jp...26F.f01t03 .
XON: 39.30 (+1.05)
InsiderInsights.com Daily Round Up 1/27/15: OKSB, OAS, XON, MLNK
InsiderInsights - at Seeking Alpha - Wed Jan 28, 10:20AM CST
MCK: 224.89 (+0.12), SFNC: 39.71 (-0.58), XON: 39.30 (+1.05), WFC: 55.33 (+0.47), MLNK: 3.78 (+0.04), GRH: 0.75 (-0.04), LUV: 43.30 (-0.20), OKSB: 16.51 (+0.09), DFS: 59.89 (+0.46), AGRX: 8.57 (-0.41), IBM: 160.40 (+1.88), CDNA: 6.30 (-0.14), FANG: 73.46 (+0.49), AAPL: 127.08 (+0.62), SNDK: 82.81 (+0.51), OAS: 16.84 (-0.03), URI: 92.98 (+1.41)
